RAB8A a new biomarker for endometrial cancer?

World Journal of Surgical Oncology

Zhenyu Zhang¹  Yachun Bie¹ 

[1] Department of Obstetrics and Gynecology, Beijing Chao-yang Hospital affiliated to Capital Medical University, No. 8 Gongti South Road, Beijing 100020, China

关键词: Biomarker;    LC-MS/MS;    Tumor lysate;    Endometrial cancer (EC);    Dendritic cells (DCs);    Proteomic analysis;   

Others  :  1147035
DOI  :  10.1186/1477-7819-12-371

 received in 2014-07-04, accepted in 2014-11-18,  发布年份 2014

【 摘 要 】

Background

We aimed to find different proteins between dendritic cells (DCs) and tumor antigen-pulsed DCs to help find a new biomarker for endometrial cancer (EC).

Methods

Mononuclear cells were isolated from cord blood and induced to DCs by cytokines. A comparative proteomic analysis was performed on DCs and tumor lysate-pulsed DCs by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Differential proteins were identified by Western blot analysis.

Results

The expression of Ras-related protein Rab-8A (RAB8A) was found to be different in the in two kinds of cells. This phenomenon was also proven in endometrial cancer tissues.

Conclusions

RAB8A might be a new biomarker for endometrial cancer. Using LC-MS/MS to perform a comparative proteomic analysis about DCs and tumor lysate-pulsed DCs may help us to find new biomarker of cancer.

【 授权许可】

   
2014 Bie and Zhang; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
• [2]Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M, Sumimoto H: Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004, 95:784-791.
• [3]Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147.
• [4]Alaniz L, Rizzo MM, Mazzolini G: Pulsing dendritic cells with whole tumor cell lysates. Methods Mol Biol 2014, 1139:27-31.
• [5]Com E, Evrard B, Roepstorff P, Aubry F, Pineau C: New insights into the rat spermatogonial proteome: identification of 156 additional proteins. Mol Cell Proteomics 2003, 2:248-261.
• [6]Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
• [7]Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
• [8]Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973, 137:1142-1162.
• [9]Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
• [10]Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC: RhoGDIalpha downregulates androgen receptor signaling in prostate cancer cells. Prostate 2013, 73:1614-1622.
• [11]Sakao K, Hahm ER, Singh SV: In vitro and in vivo effects of phenethyl isothiocyanate treatment on vimentin protein expression in cancer cells. Nutr Cancer 2013, 65(Suppl 1):61-67.
• [12]Jensen SS, Aaberg-Jessen C, Christensen KG, Kristensen B: Expression of the lysosomal-associated membrane protein-1 (LAMP-1) in astrocytomas. Int J Clin Exp Pathol 2013, 6:1294-1305.
• [13]Rong F, Li W, Chen K, Li DM, Duan WM, Feng YZ, Li F, Zhou XW, Fan SJ, Liu Y, Tao M: Knockdown of RhoGDIalpha induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel. Neoplasma 2012, 59:541-550.
• [14]Albrecht C, Huck V, Wehling M, Wendler A: In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1. Steroids 2012, 77:1543-1550.
• [15]Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP: Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch 2010, 456:377-386.
• [16]Ang AL, Taguchi T, Francis S, Folsch H, Murrells LJ, Pypaert M, Warren G, Mellman I: Recycling endosomes can serve as intermediates during transport from the Golgi to the plasma membrane of MDCK cells. J Cell Biol 2004, 167:531-543.
• [17]Wiesner C, El Azzouzi K, Linder S: A specific subset of RabGTPases controls cell surface exposure of MT1-MMP, extracellular matrix degradation and three-dimensional invasion of macrophages. J Cell Sci 2013, 126:2820-2833.
• [18]Agola JO, Jim PA, Ward HH, Basuray S, Wandinger-Ness A: Rab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunities. Clin Genet 2011, 80:305-318.
• [19]Shen DW, Gottesman MM: RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 2012, 29:643-650.
• [20]Sun Y, Bilan PJ, Liu Z, Klip A: Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells. Proc Natl Acad Sci U S A 2010, 107:19909-19914.